To do so, we examined sensitivity to various signaling pathway inhibitors as measured by mean viability (MV) across a large cancer cell line collection (Fig. 1b; Supplementary Table 2).26 Across all cell lines combined (Pan-cancer, n = 506), as well as in breast, lung, colorectal, and melanoma subgroups, cell line sensitivity correlated with MPAS for both MEK and BRAF inhibitors but not inhibitors targeting phosphoinositide-3 kinase (PI3K) (GDC-0941), AKT (GDC-0068), or other pathways (data not shown). This evidence concerns the gene BRAF and cancer.